替米沙坦联合螺内酯预防阵发性心房颤动射频消融术后早期复发的疗效

The Effect of Telmisartan Combined Therapy with Spironolactone Prevents Early Recurrence after Catheter Ablation for Paroxysmal Atrial Fibrillation

目的:探讨替米沙坦联合螺内酯预防阵发性心房颤动射频消融术后早期复发的临床疗效。方法:选择本院96例行射频消融术的阵发性心房颤动患者,随机分为观察组和对照组,每组各48例。观察组给予替米沙坦联合螺内酯治疗,对照组给予华法林及胺碘酮治疗。结果:观察组复发率为6.25%,对照组为22.92%,两组比较差异有统计学意义(P<0.05)。观察组术后1个月hs CRP高于对照组,术后3个月观察组NT-pro BNP低于对照组,两组比较差异均有统计学意义(P<0.05)。结论:替米沙坦联合螺内酯预防阵发性心房颤动射频消融术后,可减少房颤早期复发。

Objective：To clarify the effects of Telmisartan combined with Spironolactone on early recurrence after catheter ablation for paroxysmal atrial fibrillation in patients.Method：96 patients with PAF treated by catheter ablation were randomly divided into control group and observational group,48 cases in each group,the control group was treated with Warfarin and Amiodarone,the observational group was treated with Telmisartan and Spironolactone.Result：The rate of PAF early recurrence in observational group was 6.25%,which was significantly lower than 22.92% of the control group,the difference was statistically significant（P〈0.05）.After surgery 1 month,Hs CRP in observational group was higher than the control group;after surgery 3 month,NT-pro BNP in observational group was lower than the control group,the differences were statistically significant（P〈0.05）.Conclusion：Telmisartan combined with Spironolactone reduce early recurrence after catheter ablation of PAF.